PubMed Health⌕ Search

Biomedical subjects

V A Sukhanov

Publications and source records attributed to V A Sukhanov.

At least 19 recordsLinked to original sources
PubMed1996

[Isolation of growth modulating factors secreted by human malignant melanoma cells].

Novel low molecular mass growth-modulating factors-F0.5 (0.5-1.0 kDa), F1 (approximately 1 kDa) and fraction F8 (8-12 kDa)-have been isolated from a serum-free culture of human malignant pigmented melanoma mS cells using ultrafiltration, affinity and low and medium pressure gel chromatography. Factor F0.5 (10(-9)-10(-7) M) had a growth-stimulating effect on melanoma mS cells exceeding by a factor of 2 and 3 that of 5% embryonic calf serum. Factor F1 and fraction F8 inhibited melanoma cell growth when used at concentrations of 10(-9)-10(-5) M and higher than 10(-6) mg/ml, respectively. The effect of fraction F8 was concentration-dependent; that of factor F1 was more complex. The inhibiting action of fraction F8 was more pronounced when amelanotic cells of human malignant melanoma BRO were used at concentrations above 10(-8) mg/ml. Neither factors F0.5 and F1 nor fraction F8 influenced the growth of human lung fibroblast Lech 240 cells. The growth-modulating factors can participate in the autocrine regulation of malignant melanoma cell growth.

Cell Division↗
PubMed1993

[The effect of alpha-melanocyte-stimulating hormone and its analog on the growth of human melanoma cell lines with different phenotypes].

Investigation of physiological effects of alpha-MSH and its analog (NLe4, D-Phe7)-alpha-MSH on human melanoma cells with different phenotypes has shown that these peptides have a growth-modulating activity. The effect of inhibition or activation of the growth of melanoma cells depended on their phenotypes. (NLe4, D-Phe7)-alpha-MSH activated 1.5-2.5-fold the growth of amelanotic BRO cells at concentrations of 10(-6)-10(-12) M, but inhibited the growth of melanin-producing MS cells under the same conditions not affecting the growth of human lung fibroblasts.

Cell Division↗
PubMed1993

[Melanocyte-stimulating hormone induces growth of human malignant melanoma amelanotic cells with a change in cAMP, phosphatidylinositols, and inositol phosphate concentration].

The melanocyte-stimulating hormone (alpha-MSH) used at 10(-6)-5 x 10(-8) M concentrations inhibited the growth of amelanotic cells of human malignant melanoma BRO and influenced cell morphology without any effect on melanization or tyrosinase activity. Inhibition of tumour cell growth was accompanied by marked elevation of intracellular cAMP levels but not that of cGMP. Dibutyryl-cAMP and the cAMP-dependent protein kinase A inhibitor also inhibited the cell growth. alpha-MSH increased mono-, di- and 1.4.5-myoinositol triphosphate concentrations and influenced the activities of phosphatidylinositol kinase and phosphatidylinositol-4-phosphate kinase determining phosphatidylinositol-4-phosphate kinase and phosphatidylinositol-4.5-diphosphate levels. Myoinositol phosphate concentrations changed on a second scale and levelled off by the 3rd-5th min, whereas that of cAMP increased drastically by the 30th min.

Bucladesine↗
PubMed1991

Melanocyte-stimulating hormone (alpha-MSH) inhibits the growth of human malignant melanoma cells with the induction of phosphatidyl inositol and myo-inositol phosphate levels.

It has been shown that alpha-MSH inhibits the growth of amelanotic cells of human malignant melanoma (BRO) without their melanization or the expression of tyrosinase activity. alpha-MSH changed the activity of cytosol and microsomal forms of phosphatidyl inositol kinase and phosphatidyl inositol-4-phosphate kinase determining the concentration of phosphatidyl inositol-4-phosphate and phosphatidyl inositol-4,5-bisphosphate. It also induced an "outburst" in the levels of myo-inositol phosphates (mono-, bis- and 1,4,5-trisphosphates). Changes in the levels of myo-inositol phosphates occurred within seconds, and are suggested to play a certain part in the hormonal regulation of melanoma cell growth.

1-Phosphatidylinositol 4-Kinase↗
PubMed1991

[The expression of P-glycoprotein in leukemia P388 cells with induced doxorubicin resistance].

beta-D-galactose-containing glycoproteins were prepared from cells P-388 leukemia and from P-388 leukemia cells with induced resistance to doxorubicin. It was shown by HPLC method that plasma membranes from resistant cells contain 4-4.5% P-glycoproteins and plasma membranes from sensitive cells contain P-glycoproteins about 10 times lower.

ATP Binding Cassette Transporter, Subfamily B, Mem↗
PubMed1991

[A sensitive method of diagnosing hypercoagulation of the blood].

A method for the diagnosis of blood hypercoagulation is suggested, based on recalcification principle in conditions of low contact activation of the coagulation system. A specific feature of the method is employment of lesser amounts of ionized calcium than is necessary for balanced recalcification of citrate blood, promoting recovery of the initial concentration of ionized calcium. Use of this method in examinations of 232 patients has demonstrated its higher diagnostic potential in the detection of blood hypercoagulation as against balanced recalcification technique.

Blood Coagulation Disorders↗
PubMed1991

A simplified method of protein electroblotting after isoelectric focusing on an ultrathin polyacrylamide gel layer fixed on a cellophane support.

A method is described for isoelectric focusing of proteins, using an ultrathin-layer polyacrylamide gel on cellophane, followed by electrophoretic transfer of separated proteins onto a nitrocellulose membrane. The polyacrylamide gel is firmly attached to the cellophane and thus protected from mechanical damage; such gels are easily manipulated. Cellophane is permeable to ions and application of this gel support overcomes difficulties resulting from the removal of ultrathin gels from a plastic support on electroblotting. Proteins separated under nondenaturing conditions were transferred onto a nitrocellulose membrane and detected by the concanavalin A-peroxidase technique. The proposed approach makes it possible to analyze the variability of nondenatured proteins and glycoproteins of different origin.

Acrylic Resins↗
PubMed1991

[Fibrinolysis as a cause of coagulopathy in patients with chronic diffuse diseases of the liver].

Examination was performed of 74 patients with chronic diffuse diseases of the liver; chronic active hepatitis, compensated hepatitis, decompensated cirrhosis of the liver (26, 28, 20 patients, respectively). Fibrinolysis was evaluated in relation to its effect on hemocoagulation. It appeared the principal cause of coagulopathy in 3% of the examinees. It is stated that activated fibrinolysis in chronic diffuse diseases of the liver underlies coagulopathy in few patients with decompensated cirrhosis, in compensated hepatopathy the influence of fibrinolysis on overall coagulative capacity of peripheral blood is insignificant.

Adult↗
PubMed1991

[Heterogeneity of tyrosinases isolated from rat skin, normal human skin, and human melanoma tumors].

An electrophoretically homogeneous preparation of tyrosinase (Mr = 61 kDa) was isolated from rat skin. The purification procedure which consisted in chromatographic separation of Triton X-100-solubilized proteins included four main steps, namely: gel filtration, anion-exchange chromatography and two consecutive affinity chromatography steps. Isoelectrofocusing revealed the presence of 9 isoforms possessing an L-DOPA oxidase activity, of which proteins with pI of 4.26 and 4.33 were the major ones. The specific activity of the preparation was 43 nmol/min/mg of protein. Human skin epidermis was practically devoid of the L-DOPA-oxidase activity which was due not only to the absence of tyrosinase but also to the presence of a large amount of a 66 kDa protein able to inhibit the oxidation of L-DOPA to DOPA-chrom. The tyrosinase preparation from human melanoma consisted, predominantly, of two isoforms (48 and 69 kDa) which upon isoelectrofocusing displayed a high heterogeneity at pH around 3-5. The specific activity of the melanoma preparation markedly exceeded that of normal skin tyrosinase and was equal to 290 nmol/min/mg of protein.

Animals↗
PubMed1990

[The mechanisms of disorders in the hemostatic system of patients with chronic diffuse liver diseases].

A total of 70 patients with chronic hepatitis and 60 with liver cirrhosis (LC) were examined. The hemorrhagic syndrome (HS) was identified in 16% of patients with chronic active hepatitis, in 26% with compensated and in 76% with decompensated LC. Intravital study of intravascular blood coagulation and liver microcirculation with the aid of fibrin determination according to D. D. Zerbino made it possible to establish local intravascular coagulation (LIC-syndrome). Study into the hemostatic and fibrinolytic systems, analysis of liver function, hemocoagulation and the intensity of the LIC-syndrome permitted one to arrive at conclusions about complex impairments of the hemostatic system in patients with chronic diffuse liver diseases characterized by a tendency towards blood hypocoagulation in the systemic blood flow with the risk of the development of the HS and a tendency towards hypercoagulation (with the risk of thrombosis development) in the vascular bed of the liver. It has been shown that the main cause of the HS occurring in chronic diffuse liver diseases lies in derangements of the thrombocytic component of the hemostatic system: thrombocytopenia as a consequence of hypersplenism and consumption of the most active thrombocytes in the process of the LIC. Activated fibrinolysis starts to exert an inhibitory action on hemocoagulation in patients with chronic diffuse liver diseases in the stage of decompensated LC. In compensated hepatopathies, the influence of fibrinolysis on coagulation and the development of the HS was immaterial.

Blood Coagulation Disorders↗
PubMed1989

[The use of thrombolytic preparations for the functional restoration of the arteriovenous fistula in patients on programmed hemodialysis].

Administration of a thrombolytic drug of the type of streptokinase (celiase) in a dose of 250,000-1500,000 units for 40-90 minutes to the site of a thrombus with the use in necessary cases of plasminogen donors makes it possible to attain the recovery of the function of arteriovenous fistula if the treatment is carried out within the first 6-8 hours since the moment of its thrombosis. Fistula rethrombosis is the main problem that confronts one in the immediate period after successful conduction of thrombolytic therapy.

Acute Disease↗
PubMed1989

[Index of the functional state of the liver].

A combination of laboratory tests, providing the most valuable quantitative assessment of hepatic function at large was selected with the aid of an EC-1020 computer on the basis of the investigation of 124 hepatic patients and 15 normal subjects. This combination was termed the hepatic functional index (HFI); it was determined by the PTI (prothrombin index) to RETk (blood Bengal rose retention) ratio, expressed as a percentage. Quantitative criteria of normal and abnormal hepatic activity, with subdivisions by severity, have been proposed on the basis of HFI estimations in patients with varying degrees of hepatic failure and in normal subjects.

Diagnosis, Computer-Assisted↗
PubMed1989

[Prevention and treatment of hemostatic disorders in patients with liver cirrhosis].

Disorders of the different links of the hemostatic system in patients with liver cirrhosis can be corrected by simultaneous prescription of minimal doses of heparin, vicasol and curantyl. As a result, treatment of liver cirrhosis, including cases with initial manifestations of the hemorrhagic syndrome, produced significant improvement of the hemostatic parameters and abatement of this syndrome. It is expedient to include this method in the combined treatment of this category of patients.

Blood Coagulation Disorders↗